Evidence mapPaperPMID 33359363Full record

ReviewBiochemical pharmacology2021

Purinergic signaling in diabetes and metabolism.

Shanu Jain, Kenneth A Jacobson

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 53 citations in OpenAlex.

  1. COPI Coatomer Regulates Several Steps of HDL Metabolism.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Purinergic signaling in thyroid disease.Purinergic signalling · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Purinergic Signaling in Oral Tissues.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Review
  20. The Purinergic Landscape of Type 2 Diabetes Mellitus.Molecules (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shanu JainMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA.
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA. Electronic address: kennethj@niddk.nih.gov.
National Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Development of Drugs Acting at Adenosine ReceptorsZIADK031117 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$776k
Development of P2Y Receptor LigandsZIADK031116 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$647k
Development of Drugs Acting at Ion ChannelsZIADK031127 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$388k
Intramural NIH HHS ZIA DK031116Intramural NIH HHS ZIA DK031117Intramural NIH HHS ZIA DK031127
6 · The paper itself

Abstract

Purinergic signaling, a concept originally formulated by the late Geoffrey Burnstock (1929-2020), was found to modulate pathways in every physiological system. In metabolic disorders there is a role for both adenosine receptors and P2 (nucleotide) receptors, of which there are two classes, i.e. P2Y metabotropic and P2X ionotropic receptors. The individual roles of the 19 receptors encompassed by this family have been dissected - and in many cases the effects associated with specific cell types, including adipocytes, skeletal muscle, liver cells and immune cells. It is suggested that ligands selective for each of the four adenosine receptors (A

Indexed as

Adenosine TriphosphateAnimalsDiabetes MellitusHumansMetabolic DiseasesPurinergic AgonistsPurinergic AntagonistsReceptors, PurinergicSignal TransductionAdenosine TriphosphatePurinergic AgonistsPurinergic AntagonistsReceptors, PurinergicAdenosine receptorsDiabetesObesityP2X receptorsP2Y receptors

Identifiers

PMID33359363
PMCPMC8096664
OpenAlexW3113726632

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.